We are investigating the Board of Directors of Endocyte, Inc. (“Endocyte” or the “Company”) (NasdaqGS: ECYT) for possible breaches of fiduciary duty related to the sale of the company to affiliates of Novartis AG (“Novartis”). Under the terms of the agreement, Endocyte shareholders are anticipated to receive only $24.00 in cash per share they own.